MetaCap

Altimmune (ALT) vs Emergent BioSolutions (EBS)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Emergent BioSolutions (EBS) has outperformed Altimmune (ALT) over the past year, losing 49.7% versus a loss of 72.3%. Over five years, ALT leads with a -87.2% price change compared with -88.6% for EBS. Emergent BioSolutions is the larger company by market cap ($259.6 million vs $258.8 million), about 1.0 times the size, while Altimmune is growing revenue faster (+105.0% vs -28.8%).

Emergent BioSolutions converts more of its revenue into profit, with a net margin of 7.1% versus -214861.0%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ALT-72.35%EBS-49.70%
+44%-17%-78%
Nov 21, 20251 yearNov 20, 2026
ALT-87.39%EBS-87.40%
+123%+8%-107%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ALT versus EBS key metrics
MetricALTEBS
Share price$1.33$5.05
Market cap$258.80M$259.65M
1-day change-5.67%-1.94%
YTD return-63.16%-59.14%
1-year return-72.35%-49.70%
5-year return-87.24%-88.58%
Forward P/E—4.83
EPS (TTM)$-0.71$-5.00
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$41.00K$742.90M
Revenue growth (YoY)+105.00%-28.81%
Net income (latest FY)$-88.09M$52.60M
Gross margin—56.09%
Operating margin-230460.98%13.47%
Net margin-214860.98%7.08%
52-week high$6.44$14.06
52-week low$1.32$4.36
Distance from 52-week high-79.35%-64.08%
Analyst consensusstrong_buynone
Avg. price target upside+1127.82%+98.02%
Average volume3.91M1.11M
Shares outstanding194.59M51.42M
Employees57900
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • EBS has outperformed ALT by 22.6 percentage points over the past year.
  • Emergent BioSolutions is more profitable, keeping 7.1 cents of every revenue dollar as net income versus -214861.0 cents for Altimmune.
  • Altimmune grew revenue faster in its latest fiscal year (+105.00% vs -28.81%).

About Altimmune

ALT stock →

Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease.

Health Care · Biotechnology: Pharmaceutical Preparations · 57 employees

About Emergent BioSolutions

EBS stock →

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States, Canada, and internationally. It operates through Commercial Products, MCM Products, and All Other Revenues segments.

Health Care · Biotechnology: Pharmaceutical Preparations · 900 employees

ALT vs EBS FAQ

Which is bigger, Altimmune or Emergent BioSolutions?

Emergent BioSolutions (EBS) is larger, with a market capitalization of $259.65M compared with $258.80M for Altimmune (ALT).

Which stock has performed better over the past year, ALT or EBS?

EBS returned -49.70% over the past 12 months, compared with -72.35% for ALT (price return, excluding dividends). Past performance does not predict future results.

Are Altimmune and Emergent BioSolutions in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons